Protocols

Bristol-Myers’ checkpoint combo scores in PhIII study; AstraZeneca hands Circassia positive data for COPD drug; Woodford apologizes again

⇨ Bristol-Myers Squibb did get some good news on the checkpoint front today. The company says that their combination of Opdivo and Yervoy scored good results for overall survival in advanced renal cell carcinoma in their CheckMate -214 study, comparing their combo to sunitinib. Analysts say the good results for two established drugs is likely to trigger a quick OK from regulators.

⇨ The UK’s Circassia got a new lease on life after the collapse of its failed allergy meds when it licensed Duaklir and Tudorza from AstraZeneca. And now the pharma giant is handing over positive results from a COPD study that the biotech believes will open the door to a valuable US market.

⇨ DeCODE spinoff Wuxi NextCODE raised a whopping $240 million in its latest funding round, which will fuel its genomics work.

⇨ The numbers haven’t been looking so good for Neil Woodford’s big equity income fund, and he wants to let his investors know just how sorry he is. ‘I’m very sorry for the poor performance that we have delivered really since 2016,’ he said in a video posted on the fund’s website. His bottom line: Stay the course and stick with the strategy.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 19,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BioNJ CEO Summit 2017